{"id":180821,"date":"2025-09-25T12:50:07","date_gmt":"2025-09-25T12:50:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/180821\/"},"modified":"2025-09-25T12:50:07","modified_gmt":"2025-09-25T12:50:07","slug":"scisparc-launches-quantum-computing-drug-discovery-platform","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/180821\/","title":{"rendered":"SciSparc Launches Quantum Computing Drug Discovery Platform"},"content":{"rendered":"<p>&#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<\/p>\n<p>SciSparc (NASDAQ:SPRC), a clinical-stage pharmaceutical company, announced its board&#8217;s resolution to launch a groundbreaking initiative leveraging quantum computing for 3D protein modeling in drug discovery. The initiative aims to revolutionize structural biology and personalized medicine through enhanced protein structure prediction and interaction analysis.<\/p>\n<p>The company plans to establish a dedicated research team and form collaborations with quantum computing and structural biology experts. The program will focus on developing quantum-enabled tools for protein folding prediction, protein-ligand interaction modeling, and accelerated drug discovery, particularly for neurological and rare diseases. SciSparc will incorporate a new Israeli subsidiary to operate this initiative.<\/p>\n<p>SciSparc (NASDAQ:SPRC), una societ\u00e0 farmaceutica in fase clinica, ha annunciato la risoluzione del consiglio di lanciare una nuova iniziativa rivoluzionaria che sfrutta il calcolo quantistico per la modellazione 3D delle proteine nella scoperta di farmaci. L&#8217;iniziativa punta a rivoluzionare la biologia strutturale e la medicina personalizzata attraverso un miglioramento della previsione della struttura proteica e dell&#8217;analisi delle interazioni.<\/p>\n<p>La societ\u00e0 intende istituire un gruppo di ricerca dedicato e instaurare collaborazioni con esperti di calcolo quantistico e biologia strutturale. Il programma si concentrer\u00e0 sullo sviluppo di strumenti abilitati dal quantistico per la previsione del ripiegamento proteico, la modellazione delle interazioni proteina-ligando e l&#8217;accelerazione della scoperta di farmaci, in particolare per malattie neurologiche e rare. SciSparc aggiunger\u00e0 una nuova controllata israeliana per gestire questa iniziativa.<\/p>\n<p>SciSparc (NASDAQ:SPRC), una empresa farmac\u00e9utica en etapa cl\u00ednica, anunci\u00f3 la resoluci\u00f3n de su consejo de lanzar una iniciativa innovadora que aprovecha la computaci\u00f3n cu\u00e1ntica para la modelizaci\u00f3n 3D de prote\u00ednas en la discovery de f\u00e1rmacos. La iniciativa busca revolucionar la biolog\u00eda estructural y la medicina personalizada mediante una mejor predicci\u00f3n de la estructura de prote\u00ednas y el an\u00e1lisis de interacciones.<\/p>\n<p>La empresa planea establecer un equipo de investigaci\u00f3n dedicado y formar colaboraciones con expertos en computaci\u00f3n cu\u00e1ntica y biolog\u00eda estructural. El programa se centrar\u00e1 en desarrollar herramientas habilitadas por la cu\u00e1ntica para la predicci\u00f3n del plegamiento de prote\u00ednas, la modelizaci\u00f3n de interacciones prote\u00edna-ligando y la aceleraci\u00f3n del descubrimiento de f\u00e1rmacos, especialmente para enfermedades neurol\u00f3gicas y raras. SciSparc integrar\u00e1 una nueva filial en Israel para operar esta iniciativa.<\/p>\n<p>SciSparc (NASDAQ:SPRC), \uc784\uc0c1 \ub2e8\uacc4\uc758 \uc81c\uc57d\ud68c\uc0ac, \uc774\uc0ac\ud68c\uac00 \uc57d\ubb3c \ubc1c\uacac\uc5d0\uc11c 3D \ub2e8\ubc31\uc9c8 \ubaa8\ub378\ub9c1\uc744 \uc704\ud55c \uc591\uc790\ucef4\ud4e8\ud305\uc744 \ud65c\uc6a9\ud558\ub294 \ud601\uc2e0\uc801 \uc774\ub2c8\uc154\ud2f0\ube0c\ub97c \uc2dc\uc791\ud558\uae30\ub85c \uacb0\uc758\ud588\ub2e4\uace0 \ubc1c\ud45c\ud588\uc2b5\ub2c8\ub2e4. \uc774 \uc774\ub2c8\uc154\ud2f0\ube0c\ub294 \ub2e8\ubc31\uc9c8 \uad6c\uc870 \uc608\uce21 \ubc0f \uc0c1\ud638\uc791\uc6a9 \ubd84\uc11d\uc744 \ud5a5\uc0c1\uc2dc\ucf1c \uad6c\uc870\uc0dd\ubb3c\ud559\uacfc \ub9de\ucda4\uc758\ud559\uc744 \ud601\uc2e0\ud558\ub294 \uac83\uc744 \ubaa9\ud45c\ub85c \ud569\ub2c8\ub2e4.<\/p>\n<p>\ud68c\uc0ac\ub294 \uc804\ub2f4 \uc5f0\uad6c\ud300\uc744 \uc124\ub9bd\ud558\uace0 \uc591\uc790\ucef4\ud4e8\ud305 \ubc0f \uad6c\uc870\uc0dd\ubb3c\ud559 \uc804\ubb38\uac00\ub4e4\uacfc \ud611\ub825\ud558\ub294 \uac83\uc744 \uacc4\ud68d\ud569\ub2c8\ub2e4. \uc774 \ud504\ub85c\uadf8\ub7a8\uc740 \ub2e8\ubc31\uc9c8 \uc811\ud798 \uc608\uce21, \ub2e8\ubc31\uc9c8-\ub9ac\uac04\ub4dc \uc0c1\ud638\uc791\uc6a9 \ubaa8\ub378\ub9c1, \uadf8\ub9ac\uace0 \ud2b9\ud788 \uc2e0\uacbd\uacc4 \ubc0f \ud76c\uadc0 \uc9c8\ud658\uc5d0 \ub300\ud55c \uc758\uc57d\ud488 \ubc1c\uacac\uc758 \uac00\uc18d\ud654\ub97c \uc704\ud55c \uc591\uc790 \uae30\ubc18 \ub3c4\uad6c \uac1c\ubc1c\uc5d0 \uc911\uc810\uc744 \ub458 \uac83\uc785\ub2c8\ub2e4. SciSparc\ub294 \uc774 \uc774\ub2c8\uc154\ud2f0\ube0c\ub97c \uc6b4\uc601\ud558\uae30 \uc704\ud574 \uc774\uc2a4\ub77c\uc5d8\uc758 \uc0c8\ub85c\uc6b4 \uc790\ud68c\uc0ac\ub97c \uc124\ub9bd\ud569\ub2c8\ub2e4.<\/p>\n<p>SciSparc (NASDAQ:SPRC), une soci\u00e9t\u00e9 pharmaceutique en phase clinique, a annonc\u00e9 la r\u00e9solution de son conseil d&#8217;adopter une initiative r\u00e9volutionnaire tirant parti de l&#8217;informatique quantique pour la mod\u00e9lisation 3D des prot\u00e9ines dans la d\u00e9couverte de m\u00e9dicaments. L&#8217;initiative vise \u00e0 r\u00e9volutionner la biologie structurale et la m\u00e9decine personnalis\u00e9e gr\u00e2ce \u00e0 une meilleure pr\u00e9diction de la structure des prot\u00e9ines et \u00e0 l&#8217;analyse des interactions.<\/p>\n<p>La soci\u00e9t\u00e9 pr\u00e9voit de constituer une \u00e9quipe de recherche d\u00e9di\u00e9e et de former des collaborations avec des experts en informatique quantique et en biologie structurale. Le programme se concentrera sur le d\u00e9veloppement d&#8217;outils activ\u00e9s par le quantique pour la pr\u00e9diction du repliement des prot\u00e9ines, la mod\u00e9lisation des interactions prot\u00e9ine-ligand et l&#8217;acc\u00e9l\u00e9ration de la d\u00e9couverte de m\u00e9dicaments, en particulier pour les maladies neurologiques et rares. SciSparc instaurera une nouvelle filiale isra\u00e9lienne pour piloter cette initiative.<\/p>\n<p>SciSparc (NASDAQ:SPRC), ein in klinischer Erprobung befindliches pharmazeutisches Unternehmen, gab den Beschluss seines Vorstands bekannt, eine bahnbrechende Initiative zu starten, die Quantencomputing f\u00fcr die 3D-Proteinmodellierung in der Wirkstoffforschung nutzt. Die Initiative zielt darauf ab, die Strukturbio logie und die personalisierte Medizin durch verbesserte Vorhersagen von Proteinstrukturen und Interaktionsanalysen zu revolutionieren.<\/p>\n<p>Das Unternehmen plant, ein dediziertes Forschungsteam einzurichten und Kooperationen mit Experten f\u00fcr Quantencomputing und Strukturbio logie zu bilden. Das Programm konzentriert sich auf die Entwicklung von Quanten-f\u00e4higen Werkzeugen zur Vorhersage der Proteinfaltung, zur Modellierung von Protein-Ligand-Interaktionen und zur Beschleunigung der Wirkstoffentdeckung, insbesondere f\u00fcr neurologische und seltene Erkrankungen. SciSparc wird eine neue israelische Tochtergesellschaft gr\u00fcnden, um diese Initiative zu betreiben.<\/p>\n<p>SciSparc (NASDAQ:SPRC)\u060c \u0634\u0631\u0643\u0629 \u0623\u062f\u0648\u064a\u0629 \u0641\u064a \u0645\u0631\u062d\u0644\u0629 \u0625\u0643\u0644\u064a\u0646\u064a\u0643\u064a\u0629\u060c \u0623\u0639\u0644\u0646\u062a \u0639\u0646 \u0642\u0631\u0627\u0631 \u0645\u062c\u0644\u0633 \u0625\u062f\u0627\u0631\u062a\u0647\u0627 \u0628\u0625\u0637\u0644\u0627\u0642 \u0645\u0628\u0627\u062f\u0631\u0629 \u0631\u0627\u0626\u062f\u0629 \u062a\u0633\u062a\u0641\u064a\u062f \u0645\u0646 \u0627\u0644\u062d\u0648\u0633\u0628\u0629 \u0627\u0644\u0643\u0645\u0651\u064a\u0629 \u0644\u0644\u0646\u0645\u0630\u062c\u0629 \u062b\u0644\u0627\u062b\u064a\u0629 \u0627\u0644\u0623\u0628\u0639\u0627\u062f \u0644\u0644\u0628\u0631\u0648\u062a\u064a\u0646\u0627\u062a \u0641\u064a \u0627\u0643\u062a\u0634\u0627\u0641 \u0627\u0644\u0623\u062f\u0648\u064a\u0629. \u062a\u0647\u062f\u0641 \u0627\u0644\u0645\u0628\u0627\u062f\u0631\u0629 \u0625\u0644\u0649 \u0625\u062d\u062f\u0627\u062b \u062b\u0648\u0631\u0629 \u0641\u064a \u0639\u0644\u0645 \u0627\u0644\u0623\u062d\u064a\u0627\u0621 \u0627\u0644\u0628\u0646\u064a\u0648\u064a \u0648\u0627\u0644\u0637\u0628 \u0627\u0644\u0634\u062e\u0635\u064a \u0645\u0646 \u062e\u0644\u0627\u0644 \u062a\u062d\u0633\u064a\u0646 \u062a\u0646\u0628\u0624 \u0628\u0646\u064a\u0629 \u0627\u0644\u0628\u0631\u0648\u062a\u064a\u0646 \u0648\u062a\u0641\u0627\u0639\u0644\u0627\u062a\u0647.<\/p>\n<p>\u062a\u062e\u0637\u0637 \u0627\u0644\u0634\u0631\u0643\u0629 \u0644\u062a\u0623\u0633\u064a\u0633 \u0641\u0631\u064a\u0642 \u0628\u062d\u062b \u0645\u062e\u0635\u0635 \u0648\u062a\u0643\u0648\u064a\u0646 \u062a\u0639\u0627\u0648\u0646\u0627\u062a \u0645\u0639 \u062e\u0628\u0631\u0627\u0621 \u0627\u0644\u062d\u0648\u0633\u0628\u0629 \u0627\u0644\u0643\u0645\u0651\u064a\u0629 \u0648\u0639\u0644\u0645 \u0627\u0644\u0623\u062d\u064a\u0627\u0621 \u0627\u0644\u0628\u0646\u064a\u0648\u064a. \u0633\u064a\u0631\u0643\u0632 \u0627\u0644\u0628\u0631\u0646\u0627\u0645\u062c \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0623\u062f\u0648\u0627\u062a \u0645\u064f\u0634\u063a\u0651\u0644\u0629 \u0628\u0627\u0644\u0643\u0645\u0651 \u0644\u0625\u064a\u062c\u0627\u062f \u0637\u064a \u0627\u0644\u0628\u0631\u0648\u062a\u064a\u0646\u060c \u0648\u0646\u0645\u0630\u062c\u0629 \u062a\u0641\u0627\u0639\u0644\u0627\u062a \u0627\u0644\u0628\u0631\u0648\u062a\u064a\u0646-\u0644\u064a\u063a\u0627\u0646\u062f \u0648\u062a\u0633\u0631\u064a\u0639 \u0627\u0643\u062a\u0634\u0627\u0641 \u0627\u0644\u0623\u062f\u0648\u064a\u0629\u060c \u062e\u0627\u0635\u0629 \u0644\u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0639\u0635\u0628\u064a\u0629 \u0648\u0627\u0644\u0646\u0627\u062f\u0631\u0629. \u0633\u062a\u062f\u0631\u062c SciSparc \u0634\u0631\u0643\u0629 \u062a\u0627\u0628\u0639\u0629 \u0625\u0633\u0631\u0627\u0626\u064a\u0644\u064a\u0629 \u062c\u062f\u064a\u062f\u0629 \u0644\u062a\u0634\u063a\u064a\u0644 \u0647\u0630\u0647 \u0627\u0644\u0645\u0628\u0627\u062f\u0631\u0629.<\/p>\n<p>SciSparc\uff08\u7eb3\u65af\u8fbe\u514b\u80a1\u7968\u4ee3\u7801\uff1aSPRC\uff09\uff0c\u4e00\u5bb6\u5904\u4e8e\u4e34\u5e8a\u9636\u6bb5\u7684\u5236\u836f\u516c\u53f8\uff0c\u5ba3\u5e03\u5176\u8463\u4e8b\u4f1a\u4f5c\u51fa\u51b3\u5b9a\uff0c\u542f\u52a8\u4e00\u9879\u5f00\u521b\u6027\u8ba1\u5212\uff0c\u5229\u7528\u91cf\u5b50\u8ba1\u7b97\u8fdb\u884c\u86cb\u767d\u8d283D\u5efa\u6a21\u5728\u836f\u7269\u53d1\u73b0\u4e2d\u7684\u5e94\u7528\u3002\u8be5\u8ba1\u5212\u65e8\u5728\u901a\u8fc7\u6539\u8fdb\u86cb\u767d\u8d28\u7ed3\u6784\u9884\u6d4b\u548c\u76f8\u4e92\u4f5c\u7528\u5206\u6790\uff0c\u9769\u65b0\u7ed3\u6784\u751f\u7269\u5b66\u548c\u4e2a\u6027\u5316\u533b\u7597\u3002<\/p>\n<p>\u516c\u53f8\u8ba1\u5212\u7ec4\u5efa\u4e00\u4e2a\u4e13\u95e8\u7684\u7814\u7a76\u56e2\u961f\uff0c\u5e76\u4e0e\u91cf\u5b50\u8ba1\u7b97\u548c\u7ed3\u6784\u751f\u7269\u5b66\u9886\u57df\u7684\u4e13\u5bb6\u5efa\u7acb\u5408\u4f5c\u3002\u8be5\u8ba1\u5212\u5c06\u91cd\u70b9\u5f00\u53d1\u7528\u4e8e\u86cb\u767d\u6298\u53e0\u9884\u6d4b\u3001\u86cb\u767d-\u914d\u4f53\u76f8\u4e92\u4f5c\u7528\u5efa\u6a21\u4ee5\u53ca\u836f\u7269\u53d1\u73b0\u52a0\u901f\u7684\u91cf\u5b50\u9a71\u52a8\u5de5\u5177\uff0c\u7279\u522b\u662f\u9488\u5bf9\u795e\u7ecf\u75be\u75c5\u548c\u7f55\u89c1\u75c5\u3002SciSparc\u5c06\u8bbe\u7acb\u4e00\u5bb6\u65b0\u7684\u4ee5\u8272\u5217\u5b50\u516c\u53f8\u6765\u8fd0\u8425\u8fd9\u9879\u8ba1\u5212\u3002<\/p>\n<p>Positive<\/p>\n<p>          &#13;<br \/>\n            &#13;<br \/>\n                    Integration of cutting-edge quantum computing technology into drug discovery process&#13;<br \/>\n            &#13;<br \/>\n                    Potential for more accurate protein structure prediction and drug interaction modeling&#13;<br \/>\n            &#13;<br \/>\n                    Formation of dedicated research team and expert collaborations&#13;<br \/>\n            &#13;<br \/>\n                    Focus on expanding intellectual property portfolio&#13;<br \/>\n            &#13;<\/p>\n<p>Negative<\/p>\n<p>          &#13;<br \/>\n            &#13;<br \/>\n                    Early-stage initiative with no immediate revenue impact&#13;<br \/>\n            &#13;<br \/>\n                    Significant investment and resources required for quantum computing implementation&#13;<br \/>\n            &#13;<br \/>\n                    Uncertain timeline for practical applications and results&#13;<br \/>\n            &#13;<\/p>\n<p>&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n    &#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n      09\/25\/2025 &#8211; 07:05 AM&#13;<br \/>\n      &#13;<br \/>\n    &#13;<br \/>\n&#13;<\/p>\n<p>TEL AVIV, Israel, Sept.  25, 2025  (GLOBE NEWSWIRE) &#8212; SciSparc Ltd. (Nasdaq: <a href=\"https:\/\/www.stocktitan.net\/overview\/SPRC\" title=\"View SPRC stock overview\" class=\"symbol-link\" rel=\"nofollow noopener\" target=\"_blank\">SPRC<\/a>) (the &#8220;Company&#8221; or &#8220;SciSparc&#8221;), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the board of directors resolved to initiate the launch of an innovative initiative to advance 3D protein modeling using quantum computing technology (the \u201cInitiative\u201d). This new program aims to transform drug discovery by potentially achieving unprecedented accuracy in predicting protein structures and interactions with their ligands, potentially paving the way for breakthroughs in structural biology and personalized medicine.<\/p>\n<p>Proteins are the building blocks of life and their function often depends on their unique 3D shapes. Knowing a protein\u2019s 3D structure is critical for understanding how it interacts in the body, how to treat a related disease and how to design effective drugs using the highest possible level of accuracy. Traditionally, scientists use computers to predict these 3D structures, but this process is challenging because proteins are dynamic, constantly shifting between different conformations and classical computers often struggle to model these changes accurately.<\/p>\n<p>SciSparc\u2019s new Initiative aims to leverage quantum computing, a cutting-edge technology that uses principles of quantum mechanics to perform calculations far beyond the capabilities of traditional computers. Unlike classical computing methods, quantum computing might simulate the energy dynamics of proteins with greater precision, capturing their complex movements and interactions with their ligands in a much higher accuracy. This initiative focuses on developing quantum-enabled tools to:<\/p>\n<p>    accurately predict how proteins fold into their 3D shapes;model how proteins interact with potential drugs (protein-ligand interactions); andaccelerate the discovery of new drugs by providing highly precise predictions.    <\/p>\n<p>SciSparc will form a dedicated research team to integrate quantum computing algorithms into 3D protein modeling with the aim of creating new intellectual property. The Company will collaborate with leading experts in quantum computing and structural biology to build these capabilities. Initial efforts will focus on refining quantum algorithms to simulate protein dynamics and binding interactions, targeting applications in drug discovery for neurological and rare diseases, areas where SciSparc already has expertise. SciSparc expects to incorporate a new wholly owned Israeli subsidiary which will operate the Initiative.<\/p>\n<p>About\u00a0SciSparc\u00a0Ltd. (Nasdaq: <a href=\"https:\/\/www.stocktitan.net\/overview\/SPRC\" title=\"View SPRC stock overview\" class=\"symbol-link\" rel=\"nofollow noopener\" target=\"_blank\">SPRC<\/a>):<\/p>\n<p>SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc\u2019s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and\/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer\u2019s disease and agitation; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.<\/p>\n<p>Forward-Looking Statements:<\/p>\n<p>This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses: the successful launch of the Initiative, that the Company will form a dedicated research team to integrate quantum computing algorithms into 3D protein modeling; the potential benefits and advantages of the new Initiative regarding AI drug discovery; collaborating with leading experts in quantum computing and structural biology; the incorporation of a new subsidiary to operate the Initiative and that the Company\u2019s initial efforts will focus on refining quantum algorithms to simulate protein dynamics and binding interactions.. Because such statements deal with future events and are based on SciSparc\u2019s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading \u201cRisk Factors\u201d in SciSparc\u2019s Annual Report on Form 20-F filed with the SEC on\u00a0April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.<\/p>\n<p>Investor Contact:<br \/><a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=1FWM71uw_8jN3dJPsx6RakUawpdMfE0gS20p3X43pRWLzMKkH6ERdAbWaMwZ5gMXrXoec8qesmcbHOicd3Q0RQ==\" target=\"_blank\">IR@scisparc.com<\/a><a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=3NjnnQjRPiT4moUBtwqzTZ8NzDmGf4kWxk_Jv9Lrz27c08XnDsrg7Z_aCRZC0tF0s3ix4rR9hW_LjhGQdjYxyw==\" target=\"_blank\"><br \/><\/a>Tel: +972 3-761-7108<\/p>\n<p>  <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/09\/1758804607_570_ti\"\/> <br \/><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmUzNWZjMTYtNTNjYy00YWMwLWI5MmEtYjliZmEyY2FkZmJlLTUwMDEwMjUyNS0yMDI1LTA5LTI1LWVu\/tiny\/SciSparc-Ltd.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n      &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n  &#13;<br \/>\n&#13;<\/p>\n<p>&#13;<br \/>\n    FAQ  &#13;\n  <\/p>\n<p>&#13;<br \/>\n  &#13;<br \/>\n  &#13;<\/p>\n<p>        What is SciSparc&#8217;s (SPRC) new quantum computing initiative about?<\/p>\n<p>&#13;<br \/>\n          SciSparc&#8217;s initiative aims to use quantum computing technology for enhanced 3D protein modeling in drug discovery, focusing on more accurate prediction of protein structures and their interactions with potential drugs.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        How will quantum computing improve SciSparc&#8217;s drug discovery process?<\/p>\n<p>&#13;<br \/>\n          Quantum computing may enable more precise simulation of protein energy dynamics and conformational changes compared to traditional computing methods, potentially leading to more accurate drug development predictions.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        What are the main objectives of SciSparc&#8217;s quantum computing program?<\/p>\n<p>&#13;<br \/>\n          The program aims to: 1) accurately predict protein folding into 3D shapes, 2) model protein-ligand interactions, and 3) accelerate drug discovery through precise predictions, particularly for neurological and rare diseases.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        How is SciSparc implementing its quantum computing initiative?<\/p>\n<p>&#13;<br \/>\n          SciSparc will establish a dedicated research team, form collaborations with quantum computing and structural biology experts, and incorporate a new Israeli subsidiary to operate the initiative.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        What therapeutic areas will SciSparc&#8217;s quantum computing initiative focus on?<\/p>\n<p>&#13;<br \/>\n          The initiative will primarily focus on drug discovery for neurological and rare diseases, areas where SciSparc already has established expertise.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; &#13; &#13; &#13; &#13; &#13; &#13; &#13; SciSparc (NASDAQ:SPRC), a clinical-stage pharmaceutical company, announced its board&#8217;s resolution&hellip;\n","protected":false},"author":2,"featured_media":180822,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[46],"tags":[107077,107078,107081,191,24117,3635,26124,107079,107080,46953,2047,107075,107076,78679,74],"class_list":["post-180821","post","type-post","status-publish","format-standard","has-post-thumbnail","category-computing","tag-3d-protein-modeling","tag-ai-drug-development","tag-biotech-initiative","tag-computing","tag-drug-design","tag-drug-discovery","tag-neurological-disorders","tag-pharmaceutical-technology","tag-protein-folding","tag-quantum-algorithms","tag-quantum-computing","tag-scisparc","tag-sprc","tag-structural-biology","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/180821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=180821"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/180821\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/180822"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=180821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=180821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=180821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}